BF Biosciences Limited (PSX:BFBIO)

Market Cap	12.29B -9.2%
Revenue (ttm)	8.86B +78.7%
Net Income	591.76M +51.1%
EPS	6.70 +27.7%
Shares Out	88.33M
PE Ratio	20.77
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	389,835
Open	137.00
Previous Close	138.05
Day's Range	135.90 - 141.80
52-Week Range	124.00 - 190.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 22, 2026

About BF Biosciences

BF Biosciences Limited, a biotech pharmaceutical company, manufactures, imports, and sells pharmaceutical products in Pakistan, Nepal, Afghanistan, Mauritania, Switzerland, and internationally. The company offers pharmaceutical products for various therapeutic areas, including cardiometabolic disorders, cardiology, diabetes, anti-obesity, hepatology, gastroenterology, chronic kidney diseases, dermatology, antifungal treatments, antibiotics, antivirals, rheumatoid arthritis, nephrology, and oncology. It also provides injectables in vials, ampoul...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 535
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: BFBIO

Financial Performance

In fiscal year 2025, BF Biosciences's revenue was 5.84 billion, an increase of 59.55% compared to the previous year's 3.66 billion. Earnings were 447.15 million, an increase of 16.02%.